|
?:abstract
|
-
bBackground/b The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 17 million Novel therapies are urgently needed Janus kinase-inhibitors and Type I interferons have emerged as potential antiviral candidates for COVID-19 patients for their proven efficacy against diseases with excessive cytokine release and due to direct antiviral ability against viruses including coronaviruses, respectively We conducted a systemic review and meta-analysis to evaluate the effect of Janus kinase-inhibitors and Type I interferons and their ability to produce positive patient outcomes in COVID-19 patients bMethods/b A search of MEDLINE and MedRxiv was conducted by three investigators from inception until July 30 th 2020, including any study type that compared treatment outcomes of humans treated with JAK-inhibitor or Type I interferon against controls Inclusion necessitated data with clearly indicated risk estimates or those that permitted their back-calculation Outcomes were synthesized using RevMan bResults/b Of 733 searched studies, we included four randomized and eleven non-randomized trials Five of the studies were unpublished Those who received Janus kinase-inhibitor had significantly reduced odds of mortality (OR, 0 12;95% CI, 0 03 - 0 39, p0 001) and ICU admission (OR, 0 05;95% CI, 0 01 - 0 26, p0 001), and had significantly increased odds of hospital discharge (OR, 22 76;95% CI, 10 68 - 48 54, p0 00001), when compared to standard treatment group Type I interferon recipients had significantly reduced odds of mortality (OR, 0 19;95% CI, 0 04 - 0 85, p0 05), and increased odds of discharge bordering significance (OR, 1 89;95% CI, 1 00 - 3 59, p=0 05) bConclusions/b Janus kinase-inhibitor treatment is significantly associated with positive clinical outcomes in terms of mortality, ICU admission, and discharge Type I interferon treatment is associated with positive clinical outcomes in regard to mortality and discharge While these data show promise, additional well-conducted RCTs are needed to further elucidate the relationship between clinical outcomes and Janus kinase-inhibitors and Type I interferons in COVID-19 patients
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}